# A Study of Navenibart in Participants With Hereditary Angioedema

> **NCT06842823** · PHASE3 · RECRUITING · sponsor: **Astria Therapeutics, Inc.** · enrollment: 145 (estimated)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** navenibart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06842823
- **Lead sponsor:** Astria Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06842823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06842823, "A Study of Navenibart in Participants With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06842823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*